Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis C Patients: A Prospective Interventional Study

Author(s): Mohamed Alhefnawy, Ahmed Mohey, Ahmed Fathi, Ahmed Mansour, Sherief Abd-Elsalam*, Ahmed Eissa, Ayman Hagras, Stefano Puliatti and Khaled Almekaty

Volume 22, Issue 3, 2022

Published on: 12 February, 2021

Page: [310 - 317] Pages: 8

DOI: 10.2174/1871530321666210212143932

Abstract

Background & Objective: Erectile dysfunction (ED) is one of the extrahepatic manifestations of hepatitis C virus infection that greatly affects patients’ quality of life. Unfortunately, some of the drugs used for HCV treatment may have a negative impact on the patient’s erectile function, such as the pegylated interferon. Currently, with the introduction of direct-acting antiviral drugs, there is scarce data in the literature about its potential impact on erectile function. In these settings, we aimed to assess the impact of sofosbuvir-based therapy on male erectile function.

Methods: This prospective interventional study was carried out in Benha University hospitals between January 2019 and May 2020. The study included all consecutive HCV patients with simultaneous ED coming to the hepatology outpatient clinic. Patients were divided into a study group who received sofosbuvir-based therapy (group A) or a control group who received silymarin therapy (group B). The International Index of Erectile Function-5 (IIEF-5) was used for the assessment of erectile function at different time points (pretreatment, 6 months, and 12 months after treatment). Different variables in both groups have been statistically analyzed.

Results: Overall, 75 patients who received sofosbuvir-based therapy and a control group (n = 35) matched for age and pretreatment variables (Child–Turcotte–Pugh score and Fibrosis‐4 score). There was no significant difference between both groups in the pretreatment data. On the other hand, the posttreatment IIEF-5 was significantly higher in the sofosbuvir arm compared to the silymarin arm both at six months (p<0.001) and at 12 months (p<0.001). Furthermore, the age and the stage of liver fibrosis were negatively correlated with IIEF-5 at all-time points.

Conclusion: The age and the stage of liver fibrosis are significantly correlated with the degree of ED. Furthermore, sofosbuvir-based therapy may be associated with significant improvement in patients with erectile function.

Keywords: Hepatitis C virus, Sofosbuvir, andrology, sexual dysfunction, erectile dysfunction, silymarin.

« Previous Next »
Graphical Abstract

[1]
Seyam, R.M.; Albakry, A.; Ghobish, A.; Arif, H.; Dandash, K.; Rashwan, H. Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study. Int. J. Impot. Res., 2003, 15(4), 237-245.http://www.nature.com/articles/3901000
[http://dx.doi.org/10.1038/sj.ijir.3901000] [PMID: 12934050]
[2]
Allen, M.S.; Walter, E.E. Erectile dysfunction: an umbrella review of meta-analyses of risk-factors, treatment, and prevalence outcomes. J. Sex. Med., 2019, 16(4), 531-541.https://linkinghub.elsevier.com/retrieve/pii/S1743609519303546
[http://dx.doi.org/10.1016/j.jsxm.2019.01.314] [PMID: 30833150]
[3]
Fusco, F.; D’Anzeo, G.; Rossi, A.; Sciorio, C.; Buonomo, A.R.; d’Emmanuele di, Villa; Bianca, R.; Borgia, G.; Mirone, V.; Gentile, I. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin. Pharmacother., 2013, 14(18), 2533-2544.http://www.tandfonline.com/doi/full/10.1517/14656566.2013.850073
[http://dx.doi.org/10.1517/14656566.2013.850073] [PMID: 24215104]
[4]
Hunter, S.S.; Gadallah, A.; Azawi, M.K.; Doss, W. Erectile dysfunction in patients with chronic hepatitis C virus infection. Arab J. Gastroenterol., 2014, 15(1), 16-20.https://linkinghub.elsevier.com/retrieve/pii/S1687197914000161
[http://dx.doi.org/10.1016/j.ajg.2014.01.012] [PMID: 24630508]
[5]
Colaci, M.; Malatino, L.; Antonelli, A.; Fallahi, P.; Giuggioli, D.; Ferri, C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev. Endocr. Metab. Disord., 2018, 19(4), 397-403.http://link.springer.com/10.1007/s11154-018-9475-y
[http://dx.doi.org/10.1007/s11154-018-9475-y] [PMID: 30499080]
[6]
Burra, P.; Germani, G.; Masier, A.; De Martin, E.; Gambato, M.; Salonia, A.; Bo, P.; Vitale, A.; Cillo, U.; Russo, F.P.; Senzolo, M. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation, 2010, 89(12), 1425-1429.http://journals.lww.com/00007890-201006270-00001
[http://dx.doi.org/10.1097/TP.0b013e3181e1f1f6] [PMID: 20463637]
[7]
Vergniol, J.; Duc, S.; Hou, G.; Hiriart, J.B.; Foucher, J.; Chenus, F.; Fabères, C.; Chermak, F.; Lafournière, A.; Souakri, N.; de Lédinghen, V. Sexual quality of life is impaired in patients with chronic hepatitis C. Int. J. Impot. Res., 2016, 28(2), 68-73.http://www.nature.com/articles/ijir20165
[http://dx.doi.org/10.1038/ijir.2016.5] [PMID: 26865102]
[8]
Danoff, A.; Khan, O.; Wan, D.W.; Hurst, L.; Cohen, D.; Tenner, C.T.; Bini, E.J. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am. J. Gastroenterol., 2006, 101(6), 1235-1243.http://www.nature.com/doifinder/10.1111/j.1572-0241.2006.00544.x
[http://dx.doi.org/10.1111/j.1572-0241.2006.00544.x] [PMID: 16771944]
[9]
Waked, I.; Esmat, G.; Elsharkawy, A.; El-Serafy, M.; Abdel-Razek, W.; Ghalab, R.; Elshishiney, G.; Salah, A.; Abdel Megid, S.; Kabil, K.; El-Sayed, M.H.; Dabbous, H.; El Shazly, Y.; Abo Sliman, M.; Abou Hashem, K.; Abdel Gawad, S.; El Nahas, N.; El Sobky, A.; El Sonbaty, S.; El Tabakh, H.; Emad, E.; Gemeah, H.; Hashem, A.; Hassany, M.; Hefnawy, N.; Hemida, A.N.; Khadary, A.; Labib, K.; Mahmoud, F.; Mamoun, S.; Marei, T.; Mekky, S.; Meshref, A.; Othman, A.; Ragab, O.; Ramadan, E.; Rehan, A.; Saad, T.; Saeed, R.; Sharshar, M.; Shawky, H.; Shawky, M.; Shehata, W.; Soror, H.; Taha, M.; Talha, M.; Tealaab, A.; Zein, M.; Hashish, A.; Cordie, A.; Omar, Y.; Kamal, E.; Ammar, I.; AbdAlla, M.; El Akel, W.; Doss, W.; Zaid, H. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N. Engl. J. Med., 2020, 382(12), 1166-1174.http://www.nejm.org/doi/10.1056/NEJMsr1912628
[http://dx.doi.org/10.1056/NEJMsr1912628] [PMID: 32187475]
[10]
Younossi, Z.; Park, H.; Henry, L.; Adeyemi, A.; Stepanova, M. Extrahepatic Manifestations of hepatitis c: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology, 2016, 150(7), 1599-1608.https://linkinghub.elsevier.com/retrieve/pii/S0016508516002304
[http://dx.doi.org/10.1053/j.gastro.2016.02.039] [PMID: 26924097]
[11]
Omran, D.; Alboraie, M.; Zayed, R.A.; Wifi, M.N.; Naguib, M.; Eltabbakh, M.; Abdellah, M.; Sherief, A.F.; Maklad, S.; Eldemellawy, H.H.; Saad, O.K.; Khamiss, D.M.; El Kassas, M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J. Gastroenterol., 2018, 24(38), 4330-4340.http://www.wjgnet.com/1007-9327/full/v24/i38/4330.htm
[http://dx.doi.org/10.3748/wjg.v24.i38.4330] [PMID: 30344418]
[12]
El Kassas, M.; Elbaz, T.; Elsharkawy, A.; Omar, H.; Esmat, G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev. Anti Infect. Ther., 2018, 16(4), 345-350.https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1448709
[http://dx.doi.org/10.1080/14787210.2018.1448709] [PMID: 29506418]
[13]
Ahmed, O.A.; Elsebaey, M.A.; Fouad, M.H.A.; Elashry, H.; Elshafie, A.I.; Elhadidy, A.A.; Esheba, N.E.; Elnaggar, M.H.; Soliman, S.; Abd-Elsalam, S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect. Drug Resist., 2018, 11, 441-445.https://www.dovepress.com/outcomes-and-predictors-of-treatment-response-with-sofosbuvir-plus-dac-peer-reviewed-article-IDR
[http://dx.doi.org/10.2147/IDR.S160593] [PMID: 29628768]
[14]
Elshimi, E.; Morad, W.; Mohamad, N.E. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs. J. Sex. Med., 2019, 16(3), 402-409.https://linkinghub.elsevier.com/retrieve/pii/S174360951930311X
[http://dx.doi.org/10.1016/j.jsxm.2019.01.309] [PMID: 30846113]
[15]
Torgerson, D.J.; Torgerson, C.J. Unequal Randomisation BT - Designing Randomised Trials in Health, Education and the Social Sciences: An Introduction. Palgrave Macmillan, UK London., 2008, pp. 108-113.
[16]
Suk, K.T.; Kim, D.J. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J. Hepatol., 2015, 7(3), 607-615.http://www.wjgnet.com/1948-5182/full/v7/i3/607.htm
[http://dx.doi.org/10.4254/wjh.v7.i3.607] [PMID: 25848485]
[17]
Shamloul, R.; Ghanem, H.; Abou-zeid, A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int. J. Impot. Res., 2004, 16(5), 452-455.http://www.nature.com/articles/3901248
[http://dx.doi.org/10.1038/sj.ijir.3901248] [PMID: 15175638]
[18]
Triantos, C.K.; Tsintoni, A.; Karaivazoglou, K.; Grigoropoulou, X.; Tsolias, C.; Diamantopoulou, G.; Iconomou, G.; Thomopoulos, K.; Labropoulou-Karatza, C.; Assimakopoulos, K. Male hepatitis C patients’ sexual functioning and its determinants. Eur. J. Gastroenterol. Hepatol., 2017, 29(11), 1241-1246.http://journals.lww.com/00042737-201711000-00009
[http://dx.doi.org/10.1097/MEG.0000000000000971] [PMID: 28914698]
[19]
Abdelhamid, A.A.; Sherief, M.H.; Nemr, N.A.; Hassoba, H.M.; El-Sakka, A.I. Homocysteine, insulin-like growth factor one and oestrogen levels in patients with erectile dysfunction-associated chronic hepatitis C virus infection. Andrologia, 2018, 50(10), e13116.http://doi.wiley.com/10.1111/and.13116
[http://dx.doi.org/10.1111/and.13116] [PMID: 30063074]
[20]
Kraus, M.; Schafer, A.; Wismann, S. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin. Pharmacol. Ther., 2005, 77, 90-100. http://doi.wiley.com/10.1016/j.clpt.2004.09.007
[21]
Wang, F.P.; Zhang, P.A.; Yang, X.Y. Relationship between sex hormones and RIG-I signaling in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Exp. Ther. Med., 2017, 14(3), 2728-2732.https://www.spandidos-publications.com/10.3892/etm.2017.4829
[http://dx.doi.org/10.3892/etm.2017.4829] [PMID: 28962219]
[22]
Chien, Y-C.; Chiang, H-C.; Lin, P-Y.; Chen, Y.L. Erectile function in men with end-stage liver disease improves after living donor liver transplantation. BMC Urol., 2015, 15, 83.http://bmcurol.biomedcentral.com/articles/10.1186/s12894-015-0078-6
[http://dx.doi.org/10.1186/s12894-015-0078-6] [PMID: 26268947]
[23]
Chung, S.D.; Keller, J.J.; Liang, Y.C.; Lin, H.C. Association between viral hepatitis and erectile dysfunction: a population-based case-control analysis. J. Sex. Med., 2012, 9(5), 1295-1302.https://linkinghub.elsevier.com/retrieve/pii/S1743609515339849
[http://dx.doi.org/10.1111/j.1743-6109.2012.02663.x] [PMID: 22375942]
[24]
Adinolfi, L.E.; Rinaldi, L.; Nevola, R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J. Gastroenterol., 2018, 24(41), 4617-4621.http://www.wjgnet.com/1007-9327/full/v24/i41/4617.htm
[http://dx.doi.org/10.3748/wjg.v24.i41.4617] [PMID: 30416309]
[25]
Mulhall, J.P.; Luo, X.; Zou, K.H.; Stecher, V.; Galaznik, A. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int. J. Clin. Pract., 2016, 70(12), 1012-1018.http://doi.wiley.com/10.1111/ijcp.12908
[http://dx.doi.org/10.1111/ijcp.12908] [PMID: 28032424]
[26]
Dove, L.M.; Rosen, R.C.; Ramcharran, D.; Wahed, A.S.; Belle, S.H.; Brown, R.S.; Hoofnagle, J.H. Virahep-C Study Group. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 2009, 137(3), 873-884, 884.e1.https://linkinghub.elsevier.com/retrieve/pii/S0016508509009196
[http://dx.doi.org/10.1053/j.gastro.2009.05.060] [PMID: 19527724]
[27]
Foster, G.R. Quality of life considerations for patients with chronic hepatitis C. J. Viral Hepat., 2009, 16(9), 605-611.http://doi.wiley.com/10.1111/j.1365-2893.2009.01154.x
[http://dx.doi.org/10.1111/j.1365-2893.2009.01154.x] [PMID: 19674284]
[28]
Sorrell, J.H.; Brown, J.R. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl., 2006, 12(10), 1473-1477.http://doi.wiley.com/10.1002/lt.20812
[http://dx.doi.org/10.1002/lt.20812] [PMID: 16741902]
[29]
Hanafy, A.S.; Soliman, S.; Abd-Elsalam, S. Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma. Hepatol. Res., 2019, 49(4), 377-384.
[http://dx.doi.org/10.1111/hepr.13303] [PMID: 30570817]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy